US Stock Insider Trading | Vericel Discloses 11 Insider Transactions on February 26

K-LinePoet · 2026-03-23T20:41:57+00:00

Vericel Corporation conducted a series of stock sale transactions by executives and directors on February 24, 2026. Colangelo Dominick sold 8,824 shares, while other executives sold varying quantities of shares. The company focuses on the development of regenerative medicine and cell therapy.

K-LinePoet

2026-03-23 20:41:57

Abstract generation in progress

On February 26, 2026, Vericel (VCEL) disclosed 11 insider trading transactions. Director Colangelo Dominick sold 8,824 shares on February 24, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 26, 2026	Executive	Flynn Sean C.	February 24, 2026	Sell	1,331	38.25	$50,900
February 26, 2026	Executive	Halpin Michael	February 24, 2026	Sell	2,486	38.09	$94,700
February 26, 2026	Executive	Mara Joseph Anthony Jr	February 24, 2026	Sell	1,358	38.25	$51,900
February 26, 2026	Executive	Flynn Sean C.	February 24, 2026	Sell	1,553	38.09	$59,200
February 26, 2026	Executive	Hopper Jonathan Mark	February 24, 2026	Sell	1,335	38.09	$50,900
February 26, 2026	Executive	Hopper Jonathan Mark	February 24, 2026	Sell	636	38.25	$24,300
February 26, 2026	Director	Colangelo Dominick	February 24, 2026	Sell	8,824	38.09	$336,100
February 26, 2026	Executive	Mara Joseph Anthony Jr	February 24, 2026	Sell	1,358	38.09	$51,700
February 26, 2026	Executive	SIEGAL JONATHAN	February 24, 2026	Sell	627	38.09	$23,900
February 26, 2026	Executive	Halpin Michael	February 24, 2026	Sell	2,486	38.25	$95,100

[Company Profile]

Vericel Corporation, founded in 1989, is a regenerative medicine company focused on developing innovative cell therapies to repair or regenerate damaged or diseased tissues. The company is developing multi-cell therapies for patients with severe, chronic ischemic cardiovascular and cerebrovascular diseases. The company believes ixmyelocel-T is a multifunctional disease-modifying therapy that includes tissue regeneration, immune modulation, and promotion of angiogenesis. Its proprietary cell manufacturing technology enables the production of multi-cell therapies by expanding adult bone marrow and directly delivering it to damaged tissues. Preclinical and clinical data suggest that ixmyelocel-T may safely and effectively treat severe, chronic ischemic cardiovascular diseases, such as critical limb ischemia (CLI)—the most severe form of peripheral artery disease (PAD)—and dilated cardiomyopathy (DCM)—the third leading cause of heart failure.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes